Recent Updates
Recently added Catalysts
NUVB Positive Sentiment Score: 75/100

Nuvation Bio to Participate in Upcoming Investor Conferences

Key Takeaway: Nuvation Bio Inc. announced its participation in several upcoming investor conferences, including the Bank of America Securities Healthcare Conference and the H.C. Wainwright BioConnect Investor Conference. Key executives, including CEO David Hung and CFO Philippe Sauvage, will engage in fireside chats and one-on-one meetings. Live webcasts will be available on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nuvation Bio's participation in multiple investor conferences highlights its active engagement with the investment community.
  • The company's focus on innovative cancer therapies demonstrates its commitment to improving patient outcomes.
  • Live webcasts of the events will enhance accessibility for investors and stakeholders.

Full Press Release Details

NEW YORK,May 5, 2026/PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats and one-on-one meetings at the following conferences:
• Bank of America Securities 2026 Healthcare Conference – fireside chat on Wednesday, May 13, 2026, at 8:00 a.m. PT in Las Vegas, NV
• H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ – fireside chat on Tuesday, May 19, 2026, at 1:30 p.m. ET in New York, NY
• 2026 RBC Capital Markets Global Healthcare Conference – fireside chat on Wednesday, May 20, 2026, at 9:00 a.m. ET in New York, NY
• TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA – virtual fireside chat on Tuesday, May 26, 2026, at 12:00 p.m. ET
Live webcasts of each fireside chat will be available on theInvestor Relationssection of the Nuvation Bio website. An archived recording will be available for 90 days following each event.
About Nuvation BioNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visitwww.nuvationbio.comor follow the company onLinkedInand X (@nuvationbioinc).

Media and Investor Contacts

Nuvation Bio Investor ContactJR DeVita[email protected]

Nuvation Bio Media ContactKaitlyn Nealy[email protected]

SOURCE Nuvation Bio Inc.

21%

Frequently Asked Questions

Which conferences will Nuvation Bio participate in?

Nuvation Bio will participate in the Bank of America Securities Healthcare Conference, H.C. Wainwright BioConnect Investor Conference, RBC Capital Markets Global Healthcare Conference, and TD Cowen's Oncology Innovation Summit.

Who are the key executives attending the conferences?

David Hung, M.D., and Philippe Sauvage will represent Nuvation Bio at the conferences.

Will the conferences be available for online viewing?

Yes, live webcasts of each fireside chat will be available on Nuvation Bio's Investor Relations website.

What is Nuvation Bio's focus area?

Nuvation Bio is focused on developing innovative therapies for cancer treatment.

Last updated: May 5, 2026